Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × fotemustine × Clear all
NCT00110123 2012-09-24

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
171 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡